Iterum Therapeutics (ITRM) News Today → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free ITRM Stock Alerts $1.49 -0.01 (-0.67%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 5:54 AM | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Iterum Therapeutics (NASDAQ:ITRM)May 15 at 12:37 AM | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: IO Biotech (IOBT), Iterum Therapeutics (ITRM)May 14 at 7:35 PM | markets.businessinsider.comBuy Rating Affirmed for Iterum Therapeutics on Strong Market Potential and Financial StabilityMay 14 at 9:03 AM | insidermonkey.comIterum Therapeutics plc (NASDAQ:ITRM) Q1 2024 Earnings Call TranscriptMay 14 at 3:11 AM | finance.yahoo.comQ1 2024 Iterum Therapeutics PLC Earnings CallMay 13 at 10:36 AM | msn.comIterum Therapeutics Non-GAAP EPS of -$0.38 beats by $0.16May 13 at 7:00 AM | globenewswire.comIterum Therapeutics Reports First Quarter 2024 Financial ResultsMay 11, 2024 | americanbankingnews.comIterum Therapeutics (ITRM) to Release Earnings on MondayMay 6, 2024 | globenewswire.comIterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024April 29, 2024 | finanznachrichten.deIterum Therapeutics PLC: Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral SulopenemApril 29, 2024 | msn.comIterum Therapeutics resubmits new drug application to U.S. FDA for oral sulopenemApril 29, 2024 | globenewswire.comIterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral SulopenemApril 2, 2024 | finance.yahoo.comIterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call TranscriptMarch 30, 2024 | seekingalpha.comIterum Therapeutics plc (ITRM) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finance.yahoo.comQ4 2023 Iterum Therapeutics PLC Earnings CallMarch 28, 2024 | finanznachrichten.deIterum Therapeutics PLC: Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 28, 2024 | globenewswire.comIterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 21, 2024 | globenewswire.comIterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024March 15, 2024 | globenewswire.comIterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside ChatMarch 12, 2024 | markets.businessinsider.comEQS-News: Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening InnovationsMarch 6, 2024 | finance.yahoo.comIterum Therapeutics Provides Business UpdateFebruary 28, 2024 | investing.comIterum Therapeutics PLC (ITRM)February 24, 2024 | msn.comIterum Therapeutics (ITRM) Price Target Increased by 550.00% to 6.63February 1, 2024 | finance.yahoo.comSteven Cohen's Point72 Asset Management Acquires New Stake in Iterum Therapeutics PLCFebruary 1, 2024 | msn.comIterum Shareholders Reject Board’s Share Issuance ProposalJanuary 31, 2024 | msn.comIterum Therapeutics Announces Triumph in Phase 3 uUTI TrialJanuary 30, 2024 | msn.comWhy Iterum Therapeutics Stock Is Trending TodayJanuary 30, 2024 | msn.comIterum meets main goal in late trial for uUTI treatment with oral sulopenemJanuary 30, 2024 | markets.businessinsider.comIterum Therapeutics's Late-stage REASSURE Trial Successfully Met Primary EndpointJanuary 30, 2024 | marketwatch.comIterum Therapeutics Says UTI Drug Trial Met Primary EndpointJanuary 30, 2024 | marketwatch.comIterum Therapeutics Shares Surge on Positive UTI Drug Trial ResultsJanuary 30, 2024 | finance.yahoo.comIterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsJanuary 30, 2024 | marketbeat.comTrading was temporarily halted for "ITRM" at 06:01 AM with a stated reason of "News pending."December 28, 2023 | msn.comInsiders Buying Iterum Therapeutics And 3 Other Stocks Under $3November 29, 2023 | msn.comIterum Therapeutics director discloses purchase of 20K sharesNovember 15, 2023 | finance.yahoo.comIterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call TranscriptNovember 15, 2023 | finance.yahoo.comQ3 2023 Iterum Therapeutics PLC Earnings CallNovember 14, 2023 | finanznachrichten.deIterum Therapeutics PLC: Iterum Therapeutics Reports Third Quarter 2023 Financial ResultsNovember 14, 2023 | msn.comIterum Therapeutics GAAP EPS of -$0.30November 14, 2023 | benzinga.comRecap: Iterum Therapeutics Q3 EarningsNovember 14, 2023 | finance.yahoo.comIterum Therapeutics Reports Third Quarter 2023 Financial ResultsNovember 13, 2023 | msn.comIterum Therapeutics Q3 2023 Earnings PreviewNovember 13, 2023 | benzinga.comEarnings Outlook For Iterum TherapeuticsNovember 7, 2023 | finance.yahoo.comIterum Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on November 14, 2023November 5, 2023 | morningstar.comIterum Therapeutics PLC ITRMOctober 24, 2023 | finance.yahoo.comIterum Therapeutics Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract InfectionsOctober 12, 2023 | finance.yahoo.comIterum Therapeutics to Present Data at IDWeek 2023August 12, 2023 | finance.yahoo.comQ2 2023 Iterum Therapeutics PLC Earnings CallAugust 11, 2023 | finanznachrichten.deIterum Therapeutics PLC: Iterum Therapeutics Reports Second Quarter 2023 Financial ResultsAugust 11, 2023 | finance.yahoo.comIterum Therapeutics Reports Second Quarter 2023 Financial Results Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address Tiny AI projects with huge promise hiding in plain sight … (Ad)I’ve developed a system that’s helped me find huge winners in the past. Now my system has alerted me to the next four altcoins that could be the next superstars. Click here to find out who they are. ITRM Media Mentions By Week ITRM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ITRM News Sentiment▼0.680.54▲Average Medical News Sentiment ITRM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ITRM Articles This Week▼101▲ITRM Articles Average Week Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Forte Biosciences News Lisata Therapeutics News RenovoRx News Oncternal Therapeutics News Unity Biotechnology News Aptorum Group News TherapeuticsMD News Acasti Pharma News Biora Therapeutics News JanOne News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ITRM) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersAmazon's betting big on this unknown AI companyManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
